Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

oncology

- PMLiVE

ICR’s cancer cell study could offer longer-lasting protection for breast cancer patients

The condition affects over 55,000 people in the UK every year

- PMLiVE

The Power of Patient Insights to Improve Cancer Care

Two global patient advocacy groups—The Lymphoma Coalition and Lung Cancer Europe— are compiling data from their communities on the real-world experience of living with cancer. What the data reveals sometimes...

Medscape Education Global

- PMLiVE

Eli Lilly and Aktis enter $1bn partnership to develop anticancer radiopharmaceuticals

Lilly will gain rights to develop Aktis’ lead programme targeting a tumour-associated antigen

- PMLiVE

AstraZeneca unveils plans to deliver $80bn in total revenue by 2030

The company expects to launch 20 new medicines by the end of the decade

- PMLiVE

Study reveals new breast cancer genes found in women of African ancestry

More than 240,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

Trial reveals promising results for radiotherapy/hormone therapy combination in prostate cancer

Further evidence is being sought from the phase 2 TRAP trial results through the larger STAR-SHIP study

- PMLiVE

NICE recommends three tumour profiling tests for early breast cancer patients

Breast cancer is the most common cancer in the UK, affecting more than 55,000 people every year

- PMLiVE

ICR researchers reveal key driver of PARP inhibitor resistance in advanced breast cancer

Currently the most common cancer in the UK, breast cancer affects over 55,000 people annually

- PMLiVE

Johnson & Johnson shares positive results for TAR-200 in high-risk bladder cancer

More than 83,000 cases of bladder cancer are diagnosed in the US every year

- PMLiVE

New immune cell discovery could lead to personalised breast cancer treatments

The study revealed the key features of immune cells in helping the body’s immune system fight cancer

- PMLiVE

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

With rapid growth comes growing pains...

Impetus Digital

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in phase 3 breast cancer study

More than two million cases of breast cancer were diagnosed globally in 2022

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links